Home / Publications / Efficacy of Novel Syk-Kinase Inhibitors MT-SYK-03 and MT-SYK-322 in Cellular Models of Autoimmunity and Cancer

Efficacy of Novel Syk-Kinase Inhibitors MT-SYK-03 and MT-SYK-322 in Cellular Models of Autoimmunity and Cancer

Tatiana Vladimirovna Rakitina 1, 2
Tatiana Vladimirovna Rakitina
, 
Alexey A Zeifman 3, 4
Alexey A Zeifman
, 
Ilya Yur'evich Titov 3, 4
Ilya Yur'evich Titov
, 
Igor Svitanko 4
Igor Svitanko
, 
Aleksey Valer'evich Lipkin 2, 5
Aleksey Valer'evich Lipkin
, 
Viktor Sergeevich Stroylov 3, 4
Viktor Sergeevich Stroylov
, 
Oleg Valentinovich Stroganov 3, 4
Oleg Valentinovich Stroganov
, 
Fedor Nikolaevich Novikov 3, 4
Fedor Nikolaevich Novikov
, 
Ghermes Grigor'evich Chilov 3, 4
Ghermes Grigor'evich Chilov
10.1016/j.mencom.2012.11.001
Published 2012-11-07
Communication , Volume 22, Issue 6, 287-289
3
Share
Cite this
GOST
 | 
Cite this
GOST Copy
Rakitina T. V. et al. Efficacy of Novel Syk-Kinase Inhibitors MT-SYK-03 and MT-SYK-322 in Cellular Models of Autoimmunity and Cancer // Mendeleev Communications. 2012. Vol. 22. No. 6. pp. 287-289.
GOST all authors (up to 50) Copy
Rakitina T. V., Zeifman A. A., Titov I. Y., Svitanko I., Lipkin A. V., Stroylov V. S., Stroganov O. V., Novikov F. N., Chilov G. G. Efficacy of Novel Syk-Kinase Inhibitors MT-SYK-03 and MT-SYK-322 in Cellular Models of Autoimmunity and Cancer // Mendeleev Communications. 2012. Vol. 22. No. 6. pp. 287-289.
RIS
 | 
Cite this
RIS Copy
TY - JOUR
DO - 10.1016/j.mencom.2012.11.001
UR - https://mendcomm.colab.ws/publications/10.1016/j.mencom.2012.11.001
TI - Efficacy of Novel Syk-Kinase Inhibitors MT-SYK-03 and MT-SYK-322 in Cellular Models of Autoimmunity and Cancer
T2 - Mendeleev Communications
AU - Rakitina, Tatiana Vladimirovna
AU - Zeifman, Alexey A
AU - Titov, Ilya Yur'evich
AU - Svitanko, Igor
AU - Lipkin, Aleksey Valer'evich
AU - Stroylov, Viktor Sergeevich
AU - Stroganov, Oleg Valentinovich
AU - Novikov, Fedor Nikolaevich
AU - Chilov, Ghermes Grigor'evich
PY - 2012
DA - 2012/11/07
PB - Mendeleev Communications
SP - 287-289
IS - 6
VL - 22
ER -
BibTex
 | 
Cite this
BibTex (up to 50 authors) Copy
@article{2012_Rakitina,
author = {Tatiana Vladimirovna Rakitina and Alexey A Zeifman and Ilya Yur'evich Titov and Igor Svitanko and Aleksey Valer'evich Lipkin and Viktor Sergeevich Stroylov and Oleg Valentinovich Stroganov and Fedor Nikolaevich Novikov and Ghermes Grigor'evich Chilov},
title = {Efficacy of Novel Syk-Kinase Inhibitors MT-SYK-03 and MT-SYK-322 in Cellular Models of Autoimmunity and Cancer},
journal = {Mendeleev Communications},
year = {2012},
volume = {22},
publisher = {Mendeleev Communications},
month = {Nov},
url = {https://mendcomm.colab.ws/publications/10.1016/j.mencom.2012.11.001},
number = {6},
pages = {287--289},
doi = {10.1016/j.mencom.2012.11.001}
}
MLA
Cite this
MLA Copy
Rakitina, Tatiana Vladimirovna, et al. “Efficacy of Novel Syk-Kinase Inhibitors MT-SYK-03 and MT-SYK-322 in Cellular Models of Autoimmunity and Cancer.” Mendeleev Communications, vol. 22, no. 6, Nov. 2012, pp. 287-289. https://mendcomm.colab.ws/publications/10.1016/j.mencom.2012.11.001.

Abstract

Novel rationally-designed Syk-kinase inhibitor MT-SYK-03 demonstrated equal potency with R406 (active metabolite of Fostamatinib, a phase III clinical trial candidate) in cellular models of autoimmunity and cancer with EC50 values in sub-micromolar range, while MT-SYK-322 was less active.

References

1.
Therapeutic prospect of Syk inhibitors
Ruzza P., Biondi B., Calderan A.
Expert Opinion on Therapeutic Patents, 2009
2.
Treatment of rheumatoid arthritis with a syk kinase inhibitor: A twelve-week, randomized, placebo-controlled trial
Weinblatt M.E., Kavanaugh A., Burgos-Vargas R., Dikranian A.H., Medrano-Ramirez G., Morales-Torres J.L., Murphy F.T., Musser T.K., Straniero N., Vicente-Gonzales A.V., Grossbard E.
Arthritis & Rheumatism, 2008
3.
An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis
Weinblatt M.E., Kavanaugh A., Genovese M.C., Musser T.K., Grossbard E.B., Magilavy D.B.
New England Journal of Medicine, 2010
4.
Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target
Young R.M., Hardy I.R., Clarke R.L., Lundy N., Pine P., Turner B.C., Potter T.A., Refaeli Y.
Blood, 2009
5.
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
Friedberg J.W., Sharman J., Sweetenham J., Johnston P.B., Vose J.M., LaCasce A., Schaefer-Cutillo J., De Vos S., Sinha R., Leonard J.P., Cripe L.D., Gregory S.A., Sterba M.P., Lowe A.M., Levy R., et. al.
Blood, 2010
6.
Zeifman A.A., Titov I.Y., Svitanko I.V., Rakitina T.V., Lipkin A.V., Stroylov V.S., Stroganov O.V., Novikov F.N., Chilov G.G.
Mendeleev Communications, 2012
7.
Lead Finder: An Approach To Improve Accuracy of Protein−Ligand Docking, Binding Energy Estimation, and Virtual Screening
Stroganov O.V., Novikov F.N., Stroylov V.S., Kulkov V., Chilov G.G.
Journal of Chemical Information and Modeling, 2008
8.
Improving performance of docking-based virtual screening by structural filtration
Novikov F.N., Stroylov V.S., Stroganov O.V., Chilov G.G.
Journal of Molecular Modeling, 2009
9.
Spleen tyrosine kinases: biology, therapeutic targets and drugs
Riccaboni M., Bianchi I., Petrillo P.
Drug Discovery Today, 2010
10.
R406, an Orally Available Spleen Tyrosine Kinase Inhibitor Blocks Fc Receptor Signaling and Reduces Immune Complex-Mediated Inflammation
Braselmann S., Taylor V., Zhao H., Wang S., Sylvain C., Baluom M., Qu K., Herlaar E., Lau A., Young C., Wong B.R., Lovell S., Sun T., Park G., Argade A., et. al.
Journal of Pharmacology and Experimental Therapeutics, 2006